Chamow & Associates hosted a free webinar titled, "Developing Therapeutic Monoclonal Antibodies at Pandemic Pace" on August 25, 2020. The webinar addressed how the speed of CMC development can be…
Regulatory health authorities seek substantial information from sponsors regarding the practices used to generate production cell lines for mAbs and other therapeutic proteins. In an interest to promote production processes…
Chamow & Associates hosted a free, two-part webinar series titled, "What Does It Take To Develop A New Drug for COVID-19?" on June 23, 2020 and June 30, 2020. These…
We have discussed bispecific antibodies (BsAbs) in this blog before, and we would like to announce a new publication in Bioprocess International on this topic. Teneobio, Inc., a biotechnology company…
Chamow & Associates continues our blog series detailing best practices for working with a contract development and manufacturing organization (CDMO). This series is intended to provide a potential sponsor company…
Bill Gates published an insightful memo that outlines his view on the COVID-19 pandemic. He addresses the initial outbreak with an explanation of exponential growth and decline and whether the…
Competition among colleagues in science advances knowledge in the field, pushes boundaries, and leads to the production of new therapeutics. Often, companies compete against each other to develop the next…
In November of 2019, I was working for one of our clients in WuXi City, Jiangsu province when the global pandemic that became COVID-19 caught fire in Wuhan, China. Having…
Chamow & Associates is pleased to announce the launch of our new website. Our updated site was created with our valued clients, and future clients, in mind. We have introduced…
In designing cell culture processes for the manufacture of biologics, we often place the greatest focus on product titer. Titer is determined by multiplying together two factors: the amount of…